Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
Thompson, Joe Sneath
Care, Matthew A
Davies, Andrew J
Johnson, Peter WM
Springer Science and Business Media LLC
MetadataShow full item record
Cucco, F., Barrans, S., Sha, C., Clipson, A., Crouch, S., Dobson, R., Chen, Z., et al. (2020). Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.. Leukemia, 34 (5), 1329-1341. https://doi.org/10.1038/s41375-019-0691-6
Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC/BCL2 double-hit (MYC/BCL2-DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC/BCL2-DH (n = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC/BCL2-DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC/BCL2-DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.
Humans, Translocation, Genetic, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-bcl-2, Prognosis, Survival Rate, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Gene Rearrangement, Phenotype, Mutation, Middle Aged, Female, Male, Lymphoma, Large B-Cell, Diffuse, Clonal Evolution, Biomarkers, Tumor
Bloodwise (via University of Southampton) (515010)
Embargo Lift Date
External DOI: https://doi.org/10.1038/s41375-019-0691-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/299198
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/